SEATTLE, May 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. today announced it plans to issue earnings results for the first quarter-ended 2007 after the close of market on May 14, 2007. The Company’s earnings conference call will take place the same day at 2 p.m. Pacific Time; 5 p.m. Eastern Time.
The live event will be available from Trubion’s website at http://investors.trubion.com/events.cfm, or by calling 1-800-819-9193 or 1-913-981-4911. A replay of the discussion will be available beginning May 14, 2007 from Trubion’s website or by calling 1-888-203-1112 or 1-719-457-0820, and entering 6425828. The telephone replay will be available through May 18, 2007.
About Trubion
Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The Company’s product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the Company designed, developed and submitted to the FDA an Investigational New Drug application for its lead product candidate, TRU-015, which is currently being tested in a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the Company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion’s TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the Company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit www.trubion.com.
Forward Looking Statements
Certain statements in this release may constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company’s future clinical development programs and the timing thereof, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, those identified in the company’s annual report on Form 10-K for the period ended December 31, 2006 and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company’s corporate website at www.trubion.com. Trubion undertakes no duty to update any forward- looking statement to conform the statement to actual results or changes in the company’s expectations.
TRBN-G Jim DeNike Senior Director, Corporate Communication Trubion Pharmaceuticals, Inc. 1-206-838-0500 jdenike@trubion.comhttp://www.trubion.com
Trubion Pharmaceuticals, Inc.
CONTACT: Jim DeNike, Senior Director, Corporate Communication of TrubionPharmaceuticals, Inc., +1-206-838-0500, jdenike@trubion.com
Web site: http://www.trubion.com//
